“To Randomize, or Not to Randomize, That is the Question”
Authors:
- Nicolino RupertoNRNicolino Ruperto
- Alberto MartiniAMAlberto Martini
- Angela PistorioAPAngela Pistorio
- for the Paediatric Rheumatology International Trials OrganisationFOfor the Paediatric Rheumatology International Trials Organisation
- 1 July 2021
- journal article
- editorial
- Published by Wiley in Arthritis & Rheumatology
- Vol. 73 (10) , 1776-1779
Abstract
Until the end of the last century there were no drugs approved for the treatment of juvenile idiopathic arthritis (JIA). This situation was revolutionized in the past 20 years thanks to 3 factors: the introduction in the USA and in Europe of paediatric legislations(1, 2), the availability of biologic disease-modifying anti-rheumatic drugs (b-DMARDs), and the existence of not-for-profit organizations with the mission to foster, facilitate and co-ordinate the development, conduct, analysis, and reporting of multi-centres studies in children with paediatric rheumatic diseases.Keywords
This publication has 14 references indexed in Scilit:
- 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non‐Systemic Polyarthritis, Sacroiliitis, and EnthesitisArthritis & Rheumatology, 2019
- The Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment PlansArthritis & Rheumatology, 2018
- A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunitiesPediatric Rheumatology, 2017
- Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for New‐Onset Polyarticular Juvenile Idiopathic ArthritisArthritis Care & Research, 2013
- Impact of the European paediatric legislation in paediatric rheumatology: past, present and futureAnnals of the Rheumatic Diseases, 2013
- Ethics bureaucracy: a significant hurdle for collaborative follow-up of drug effectiveness in rare childhood diseasesArchives of Disease in Childhood, 2012
- American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritisArthritis Care & Research, 2011
- Is it time to move to active comparator trials in juvenile idiopathic arthritis?: A review of current study designsArthritis & Rheumatism, 2010
- Development and validation of a composite disease activity score for juvenile idiopathic arthritisArthritis Care & Research, 2009
- The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trialsThe Lancet, 2001